QUICKHEAL:NSE:NSE-Quick Heal Technologies Limited (INR)

COMMON STOCK | Software - Application |

Last Closing

USD 602.65

Change

+1.45 (+0.24)%

Market Cap

USD 32.32B

Volume

0.19M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Quick Heal Technologies Limited engages in the provision of security software products and solutions to consumers, small businesses, government establishments, and corporate houses in India and internationally. The company operates through Consumer, and Enterprise and Government segments. It offers antivirus solutions, including total security, internet security, antivirus pro, security for mac, total security for android, mobile security, total security multi-device, internet security essential, and total security-festive pack under the Quick Heal brand. The company provides endpoint protection, endpoint protection cloud, EDR, XDR, MDR, ZTNZ, enterprise mobility management, workspace, and data privacy under the Seqrite brand. It sells its products to national distributors, primary dealers, business partners, and website and e-commerce. Quick Heal Technologies Limited was incorporated in 1995 and is based in Pune, India.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-05 )

Largest Industry Peers for Software - Application

Symbol Name Price(Change) Market Cap
TATAELXSI:NSE Tata Elxsi Limited

-3.50 (-0.05%)

USD 437.43B
KFINTECH:NSE Kfin Technologies Limited

+15.85 (+1.57%)

USD 170.18B
INTELLECT:NSE Intellect Design Arena Limited

+5.75 (+0.78%)

USD 102.32B
TANLA:NSE Tanla Platforms Limited

-10.20 (-1.36%)

USD 101.25B
RATEGAIN:NSE Rategain Travel Technologies L..

-5.35 (-0.67%)

USD 89.46B
BBOX:NSE Black Box Limited

+20.85 (+4.15%)

USD 87.70B
EMUDHRA:NSE eMudhra Limited

+0.10 (+0.01%)

USD 73.81B
NUCLEUS:NSE Nucleus Software Exports Limit..

+14.10 (+1.17%)

USD 31.40B
GENESYS:NSE Genesys International Corporat..

+29.75 (+3.87%)

USD 30.74B
63MOONS:NSE 63 moons technologies limited

+7.90 (+1.36%)

USD 27.17B

ETFs Containing QUICKHEAL:NSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Software - Application) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 69.95% 85% B 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 69.95% 85% B 90% A-
Trailing 12 Months  
Capital Gain 80.52% 81% B- 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 80.52% 81% B- 87% B+
Trailing 5 Years  
Capital Gain 332.32% 50% F 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 332.32% 50% F 76% C+
Average Annual (5 Year Horizon)  
Capital Gain 63.92% 50% F 76% C+
Dividend Return 65.42% 50% F 76% C+
Total Return 1.50% 78% C+ 77% C+
Risk Return Profile  
Volatility (Standard Deviation) 90.03% 58% F 20% F
Risk Adjusted Return 72.67% 58% F 54% F
Market Capitalization 32.32B 71% C- 56% F

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector